On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...

The FDA has approved Karuna/Bristol Myers Squibb’s KarXT (Cobenfy) — an oral dual M1/M4 muscarinic acetylcholine receptor (mAChR) agonist — for schizophrenia. The fixed-dose combination of ...

The first new kind of treatment for schizophrenia patients in decades is arriving. The U.S. Food and Drug Administration ...

The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

Karuna’s lead candidate, KarXT (xanomeline–trospium) is an oral dual M1/M4 muscarinic acetylcholine receptor (mAChR) agonist in development for schizophrenia. The potential first-in-class ...

Background: Many neuromuscular blockers act as negative allosteric modulators of muscarinic acetylcholine receptors by decreasing affinity and potency of acetylcholine. The neuromuscular blocker ...

Cobenfy was approved to reduce the psychotic symptoms associated with schizophrenia. It is a new type of medicine that works ...

Kent Keyser. She joined the faculty of the Department of Vision Sciences at UAB in May 2011. Dr. Strang’s primary research focus is the study of the expression patterns and physiological roles of ...

The FDA is set to make a pivotal decision Sept. 26 about KarXT, a novel antipsychotic developed by Karuna Therapeutics. If approved, it would be the first drug with a unique mechanism for treating ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Serotonin (5-hydroxytryptamine [5-HT]) receptor subtypes, such as the 5-HT 1A receptor, are considered to mediate the ability of antipsychotic drugs to enhance cognition. On the other hand ...